Latest filings (excl ownership)
S-8
Registration of securities for employees
15 Apr 24
10-Q
2024 Q3
Quarterly report
12 Feb 24
8-K
Results of Operations and Financial Condition
12 Feb 24
8-K
Regulation FD Disclosure
9 Jan 24
8-K
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
20 Dec 23
8-K
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
28 Nov 23
S-3ASR
Automatic shelf registration
9 Nov 23
10-Q
2024 Q2
Quarterly report
9 Nov 23
8-K
Results of Operations and Financial Condition
9 Nov 23
424B5
Prospectus supplement for primary offering
29 Sep 23
8-K
Entry into a Material Definitive Agreement
28 Sep 23
FWP
Free writing prospectus
28 Sep 23
FWP
Free writing prospectus
26 Sep 23
424B5
Prospectus supplement for primary offering
26 Sep 23
8-K
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
26 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
23 Aug 23
10-Q
2024 Q1
Quarterly report
10 Aug 23
8-K
Results of Operations and Financial Condition
10 Aug 23
DEFA14A
Additional proxy soliciting materials
26 Jun 23
DEF 14A
Definitive proxy
26 Jun 23
10-K
2023 FY
Annual report
22 May 23
8-K
Results of Operations and Financial Condition
22 May 23
S-8
Registration of securities for employees
5 Apr 23
8-K
Other Events
27 Mar 23
S-8
Registration of securities for employees
3 Feb 23
10-Q
2023 Q3
Quarterly report
3 Feb 23
8-K
Results of Operations and Financial Condition
3 Feb 23
8-K
Other Events
9 Jan 23
8-K
Regulation FD Disclosure
8 Dec 22
10-Q
2023 Q2
Quarterly report
4 Nov 22
8-K
Results of Operations and Financial Condition
4 Nov 22
424B5
Prospectus supplement for primary offering
5 Oct 22
8-K
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
4 Oct 22
8-K
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
28 Sep 22
8-K
Regulation FD Disclosure
7 Sep 22
8-K
Submission of Matters to a Vote of Security Holders
19 Aug 22
10-Q
2023 Q1
Quarterly report
5 Aug 22
8-K
Results of Operations and Financial Condition
5 Aug 22
DEFA14A
Additional proxy soliciting materials
30 Jun 22
DEF 14A
Definitive proxy
30 Jun 22
Latest ownership filings
4
Mark S. Levine
19 Apr 24
4
William L. Macias
19 Apr 24
4
Eva Renee Barnett
19 Apr 24
4
Julia G. Butchko
19 Apr 24
4
Peter Salzmann
19 Apr 24
4
Eva Renee Barnett
10 Apr 24
4
Julia G. Butchko
10 Apr 24
4
Peter Salzmann
10 Apr 24
4
Andrew J. Fromkin
4 Apr 24
4
Douglas J. Hughes
4 Apr 24
4
GEORGE V MIGAUSKY
4 Apr 24
4
Atul Pande
4 Apr 24
4
Frank Torti
4 Apr 24
4
Jay S Stout
4 Apr 24
4
Mark S. Levine
4 Apr 24
4
William L. Macias
4 Apr 24
4
Michael Geffner
4 Apr 24
4
Julia G. Butchko
4 Apr 24
4
Eva Renee Barnett
4 Apr 24
4
Peter Salzmann
4 Apr 24
4
Eva Renee Barnett
23 Feb 24
4
Mark S. Levine
23 Feb 24
4
William L. Macias
23 Feb 24
4
Julia G. Butchko
23 Feb 24
4
Peter Salzmann
23 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G
FMR LLC
9 Feb 24
4
Mark S. Levine
29 Jan 24
4
Michael Geffner
29 Jan 24
4
William L. Macias
19 Jan 24
3
Michael Geffner
16 Jan 24
4
Eva Renee Barnett
12 Jan 24
4
Julia G. Butchko
9 Jan 24
4
Peter Salzmann
9 Jan 24
4
Andrew J. Fromkin
5 Dec 23
4
Atul Pande
5 Dec 23
4
GEORGE V MIGAUSKY
5 Dec 23
144
Notice of proposed sale of securities
1 Dec 23
144
Notice of proposed sale of securities
1 Dec 23
144
Notice of proposed sale of securities
1 Dec 23